Since the effect of ANGPTL3 inhibition on lipid levels is independent of LDLR function [17], ANGPTL3 inhibitors may benefit hypercholesterolemia patients who do not respond sufficiently to statin or PCSK9 therapy, and further reduce CVD risks for patients who are already on statin or PCSK9 drugs. The gene discussed is PCSK9; the disease is Hypercholesterolemia.